CB Oncology Partners (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Sep. 02, 2017
Condensed Income Statement Information [Abstract]
Patient revenue		$ 662,000	$ 658,000	$ 2,005,000	$ 2,324,000
USNC's equity in loss		(56,000)	(135,000)	(292,000)	(799,000)
Condensed Balance Sheet Information [Abstract]
Current assets		2,699,000		2,699,000		$ 2,681,000
Total assets		4,415,000		4,415,000		4,997,000
Current liabilities		790,000		790,000		1,638,000
Total liabilities and deficit		4,415,000		4,415,000		4,997,000
CB Oncology Partners LLC [Member]
CB Oncology Partners [Abstract]
Ownership percentage	28.58%						24.00%
Capital called from members	$ 500,000
Advances converted into equity	121,000
Contribution in cash	$ 212,000
Outstanding amount		2,162,000		2,162,000		2,207,000
Outstanding amount, less allowances		1,252,000		1,252,000		1,207,000
Due from related parties		$ 910,000		$ 910,000
Note bearing interest		6.00%		6.00%
Interest earned from the amounts owed by entity				$ 94,000	73,000
Accrued interest		$ 242,000		242,000		148,000
CB Oncology Partners LLC [Member] | Investment in Unconsolidated Entity [Member]
Condensed Income Statement Information [Abstract]
Patient revenue		466,000	399,000	1,360,000	1,147,000
Net loss		(165,000)	(309,000)	(565,000)	(882,000)
USNC's equity in loss		(48,000)	$ (75,000)	(148,000)	$ (214,000)
Condensed Balance Sheet Information [Abstract]
Current assets		470,000		470,000		380,000
Noncurrent assets		4,421,000		4,421,000		4,869,000
Total assets		4,891,000		4,891,000		5,249,000
Current liabilities		3,115,000		3,115,000		3,026,000
Noncurrent liabilities		3,820,000		3,820,000		4,019,000
Deficit		(2,044,000)		(2,044,000)		(1,796,000)
Total liabilities and deficit		$ 4,891,000		$ 4,891,000		$ 5,249,000